Topical Administration of Somatostatin Prevents Retinal Neurodegeneration in Experimental Diabetes

(Downloading may take up to 30 seconds. If the slide opens in your browser, select File -> Save As to save it.)

Click on image to view larger version.

FIG. 5.
FIG. 5.

Dose-response effect of SST eye drops on retinal neurodegeneration. A: GFAP immunofluorescence (green) corresponding to representative samples of retina from a control rat (A1), a diabetic rat treated with vehicle eye drops (A2), and diabetic rats treated with SST eye drops at doses of 0.5 mg/mL (A3), 2 mg/mL (A4), and 10 mg/mL (A5). B: Quantification of glial activation based on extent of GFAP staining corresponding to all rats (n = 8) of each group. C: Images of apoptosis assessed by TUNEL assay (green) in representative samples of retina from a control rat (C1), a diabetic rat treated with vehicle eye drops (C2), and diabetic rats treated with SST eye drops at doses of 0.5 mg/mL (C3), 2 mg/mL (C4), and 10 mg/mL (C5). D: Percentage of apoptotic cells in the retinal layers in each group (n = 8). Results are expressed as median (range). Control, control rats; D-sham, diabetic rats treated with vehicle eye drops; D-SST, diabetic rats treated with SST eye drops; INL, inner nuclear layer. *P < 0.05 in comparison with diabetic group treated with vehicle. Scale bar = 20 μm.

This Article

  1. Diabetes vol. 62 no. 7 2569-2578